Mustang Bio Inc  

(Public, NASDAQ:MBIO)   Watch this stock  
Find more results for MBIO
+0.18 (1.63%)
Real-time:   1:17PM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 10.91 - 11.45
52 week 8.06 - 13.35
Open 11.11
Vol / Avg. 18,373.00/87,768.00
Mkt cap 293.54M
P/E     -
Div/yield     -
EPS -0.96
Shares 26.23M
Beta     -
Inst. own 3%

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -39.28% -92.03%
Return on average equity -41.49% -125.62%
CDP Score - -


2 Gansevoort St Fl 9
NEW YORK, NY 10014-1667
United States - Map
+1-781-6524507 (Phone)
+1-302-5313150 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Mustang Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to utilize the power of the patient’s own immune system to eliminate cancer cells. It seeks to acquire rights to technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development and eventually either out-licensing or bringing the technologies to market. The Company is developing its proprietary Chimeric Antigen Receptor (CAR) engineered T cells (CAR -T) technology, which uses the patient’s own T cells to engage and destroy specific tumors. The Company, through its agreement with City of Hope National Medical Center, is using three novel CAR T therapies in the development of cancer treatments, including human epidermal growth factor receptor 2 CAR T technology, CS1-specific CAR T technology, and prostate stem cell antigen CAR T technology.